Polaris Financial Partners Makes New $1.07 Million Investment in Global X Genomics & Biotechnology ETF $GNOM

Polaris Financial Partners bought a new stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,041 shares of the company’s stock, valued at approximately $1,067,000. Polaris Financial Partners owned approximately 1.03% of Global X Genomics & Biotechnology ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Bank of America Corp DE increased its position in Global X Genomics & Biotechnology ETF by 67.8% in the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after buying an additional 48,394 shares in the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of NASDAQ GNOM traded up $0.84 during trading on Friday, hitting $69.62. The company had a trading volume of 16,757 shares, compared to its average volume of 19,110. Global X Genomics & Biotechnology ETF has a 12 month low of $40.17 and a 12 month high of $71.10. The firm has a market capitalization of $101.65 million, a P/E ratio of -29.75 and a beta of 1.17. The stock has a 50 day simple moving average of $62.76 and a 200 day simple moving average of $53.68.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.